PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Loncastuximab Tesirine→

Loncastuximab Tesirine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1879918-31-6
Molecular formula
Not available
Molecular weight
Not available
Drug class
CD19-directed antibody-drug conjugate (ADC)pyrrolobenzodiazepine (PBD) alkylating antineoplastic
Mechanism of action
The anti-CD19 IgG1 antibody binds CD19 on B-lineage cells and is internalised. Proteolytic cleavage releases the SG3199 PBD dimer payload, which binds the DNA minor groove and forms interstrand crosslinks, leading to cell death.
Indications / reported uses
  • Treatment of adults with relapsed or refractory large B-cell lymphoma after at least two prior systemic treatment lines, under the current product label.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=af54af12-3edf-4301-8bc5-0446bc813c1d · https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761196s013lbl.pdf

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Loncastuximab Tesirine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Loncastuximab Tesirine Permitted Daily Exposure (PDE) report (the Loncastuximab Tesirine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Loncastuximab Tesirine Occupational Exposure Limit (OEL) report (the Loncastuximab Tesirine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.